ผลของไตรโคลชานต่อเชลล์มะเร็งปอดมนุษย์ชนิดไม่ใช่เชลล์เล็ก เอช 460 ที่ดื้อต่อการตายแบบ อะนอยคิส

นางสาวธิดารัตน์ วินิจธนา



วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรดุษฎีบัณฑิต สาขาวิชาเภสัชศาสตร์ชีวภาพ คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ปีการศึกษา 2556 ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย





EFFECTS OF TRICLOSAN ON ANOIKIS-RESISTANT HUMAN NON-SMALL CELL LUNG CANCER H460 CELLS

Miss Thidarat Winitthana

=

A Dissertation Submitted in Partial Fulfillment of the Requirements

for the Degree of Doctor of Philosophy Program in Biopharmaceutical Sciences

Faculty of Pharmaceutical Sciences

Chulalongkorn University

Academic Year 2013

Copyright of Chulalongkorn University

Thesis Title EFFECTS OF TRICLOSAN ON ANOIKIS-RESISTANT HUMAN NON-SMALL CELL LUNG CANCER H460 **CELLS** Miss Thidarat Winitthana Ву Field of Study Biopharmaceutical Sciences Thesis Advisor Assistant Professor Pithi Chanvorachote, Ph.D. Associate Professor Police Lieutenant Colonel Thesis Co-Advisor Somsong Lawanprasert, Ph.D. Accepted by the Faculty of Pharmaceutical Sciences, Chulalongkorn University in Partial Fulfillment of the Requirements for the Doctoral Degree Dean of the Faculty of Pharmaceutical Sciences (Assistant Professor Rungpetch Sakulbumrungsil, Ph.D.) THESIS COMMITTEE Ratenga L. Chairman (Assistant Professor Rataya Luechapudiporn, Ph.D.) Prim chamale Thesis Advisor (Assistant Professor Pithi Chanvorachote, Ph.D.) Pol. Lt. Col. Survey Largound Thesis Co-Advisor (Associate Professor Police Lieutenant Colonel Somsong Lawanprasert, Ph.D.) clali Winotesaythy Examiner (Associate Professor Mali Wirotesangthong, Ph.D.) Neeropmy fraimacheal Examiner (Weerapong Prasongchean, Ph.D.) External Examiner (Hasseri Halim, Ph.D.)

ธิดารัตน์ วินิจธนา : ผลของไตรโคลซานต่อเซลล์มะเร็งปอดมนุษย์ชนิดไม่ใช่เซลล์เล็ก เอช 460 ที่ดื้อต่อการตายแบบอะนอยคิส. (EFFECTS OF TRICLOSAN ON ANOIKIS-RESISTANT HUMAN NON-SMALL CELL LUNG CANCER H460 CELLS) อ.ที่ ปรึกษาวิทยานิพนธ์หลัก: ผศ. ดร. ปิติ จันทร์วรโชติ, อ.ที่ปรึกษาวิทยานิพนธ์ร่วม: รศ. พ.ต.ท.หญิง ดร. สมทรง ลาวัณย์ประเสริฐ, 124 หน้า.

การเปลี่ยนแปลงลักษณะเชลล์จากอีพิธีเลียลเป็นเชลล์มีเซ็นไคมอล (epithelial-tomesenchymal transition; EMT) เป็นสาเหตุหนึ่งที่ทำให้เชลล์มะเร็งมีความรนแรงเพิ่มมากขึ้น เนื่องจากมีผลเพิ่มการแพร่กระจายของเซลล์มะเร็ง งานวิจัยนี้เป็นการรายงานถึงผลของไตรโคล ชาน ซึ่งใช้เป็นสารฆ่าเชื้อแบคทีเรียในผลิตภัณฑ์ต่างๆ ต่อการเหนี่ยวนำให้เกิดกระบวนการ EMT ในเชลล์มะเร็งปอดของมนุษย์ที่ดื้อต่อการตายแบบอะนอยคิส โดยกระบวนการ EMT กระบวนการที่ทำให้เซลล์มะเร็งเพิ่มความสามารถในการเคลื่อนที่และการรุกราน รวมถึงเพิ่ม ความสามารถในการสร้างมะเร็งก้อนใหม่อีกด้วย ในงานวิจัยนี้เชลล์มะเร็งที่ดื้อต่อการตายแบบอะ นอยคิสได้รับไตรโคลชานในความเข้มข้นที่สัมพันธ์กับระดับของสารที่พบในร่างกายมนุษย์ จาก การศึกษาพบว่าไตรโคลซานมีผลทำให้เซลล์มะเร็งลดการเกาะกันระหว่างเชลล์ซึ่งเป็นลักษณะ สำคัญของเซลล์ที่ผ่านกระบวนการ EMT และเมื่อศึกษากลไกการออกฤทธิ์ของไตรโคลซานด้วย วิธีการ western blot analysis พบว่า ไตรโคลชานมีผลทำให้ระดับของ E-cadherin ในเชลล์ ลดลงอย่างมีนัยสำคัญทางสถิติ และเพิ่มการแสดงออกของ EMT markers ได้แก่ N-cadherin, vimentin, snail และ slug อย่างมีนัยสำคัญทางสถิติอีกด้วย ซึ่งแสดงให้เห็นว่าเชลล์มะเร็งที่ได้รับ ไตรโคลชานมีลักษณะเป็นมีเซ็นไคมอลเพิ่มมากขึ้น และเมื่อศึกษาด้วยวิธีการ tumor formation assay พบว่าการเหนี่ยวนำให้เกิด EMT ด้วยไตรโคลซานยังมีผลเพิ่มการสามารถในการสร้าง โคโลนีของเซลล์มะเร็งอย่างมีนัยสำคัญทางสถิติ นอกจากนี้การเหนี่ยวนำให้เกิด EMT ด้วยไตรโคล ชานยังมีผลกระตุ้นการทำงานของ focal adhesion kinase/ATP dependent tyrosine kinase (FAK/Akt) และ Ras-related C3 botulinum toxin substrate 1 (Rac1) จึงทำให้ เซลล์มะเร็งมีความสามารถในการเคลื่อนที่และการรุกรานเพิ่มมากขึ้น ดังนั้นจึงกล่าวโดยสรุปได้ว่า การศึกษานี้เป็นการรายงานถึงผลการเหนี่ยวนำของไตรโคลซานให้เกิด EMT ในเซลล์มะเร็งปอด ของมนุษย์ที่ดื้อต่อการตายแบบอะนอยคิส ซึ่งมีผลเพิ่มความสามารถในการสร้างโคโลนีของ เซลล์มะเร็งและความสามารถในการเคลื่อนที่ของเซลล์มะเร็ง โดยคุณสมบัติที่ได้กล่าวมานี้เป็น ปัจจัยสำคัญที่มีผลทำให้เซลล์มะเร็งเกิดการแพร่กระจายได้มากยิ่งขึ้น ผลการศึกษานี้ทำให้ได้ ข้อมูลใหม่ด้านพิษวิทยาของไตรโคลชาน โดยเฉพาะอย่างยิ่งข้อมูลประกอบการพิจารณาใช้สารนี้ ในผู้ป่วยมะเร็งต่อไป

สาขาวิชา เภสัชศาสตร์ชีวภาพ ปีการศึกษา 2556

ลายมือชื่อนิสิต <u>วัดโตร์ วังคุ</u> ลายมือชื่อ อ.ที่ปรึกษาวิทยานิพนธ์หลัก ลายมือชื่อ อ.ที่ปรึกษาวิทยานิพนธ์ร่วม (การ์)



5376971633 : MAJOR BIOPHARMACEUTICAL SCIENCES

KEYWORDS: TRICLOSAN / EPITHELIAL TO MESENCHYMAL TRANSITION / LUNG CANCER / CANCER AGGRESSIVENESS

> THIDARAT WINITTHANA: EFFECTS OF TRICLOSAN ON ANOIKIS-RESISTANT HUMAN NON-SMALL CELL LUNG CANCER H460 CELLS. ADVISOR: ASST. PROF. PITHI CHANVORACHOTE, Ph.D., CO-ADVISOR: ASSOC. PROF. POL. LT. COL. SOMSONG LAWANPRASERT, Ph.D., 124 pp.

Alteration of epithelial cancer cell toward mesenchymal phenotype (epithelial-to-mesenchymal transition; EMT) has been shown to potentiate tumor aggressiveness by increasing cancer cell metastasis. Herein, the present study demonstrates the effect of triclosan, a widely used antibacterial agent found in many daily products, in enhancing the EMT in aggressive anoikis resistant human lung cancer cells. EMT was long known to increase abilities of cancer cells to increase migration and invasion as well as tumorigenicity of cells. The present study reveals that treatment of the anoikis resistant cells with triclosan at the physiologically-related concentrations significantly decreased cell to cell adhesion which is a dominant characteristic of cell undergoing EMT. Importantly, western blot analysis revealed that triclosan-treated cells exhibited decreased E-cadherin, while the levels of EMT markers, namely N-cadherin, vimentin, snail and slug were found to be significantly up-regulated, indicating mesenchymal phenotype of cells. Also, EMT-induced by triclosan treatment increased the colony number of the cancer cells assessed by tumor formation assay. Furthermore, EMT-induced by triclosan treatment was accompanied by the activation of focal adhesion kinase/ATP dependent tyrosine kinase (FAK/Akt) and Ras-related C3 botulinum toxin substrate 1 (Rac1) which enhanced ability of the cells to migrate and invade. In conclusion, this study demonstrated that triclosan may potentiate tumorigenicity and motility of anoikis resistant human lung cancer cells via the process of EMT. As mentioned capabilities are required for success in metastasis, the present study provides the novel toxicological information and encourages the awareness of triclosan use in cancer patients

Field of Study: Biopharmaceutical

Sciences

Academic Year: 2013

Student's Signature Thiology Wmithana

Co-Advisor's Signature Pot. Lt. Col. Sumy Lub

Advisor's Signature Pthi Eut



ACKNOWLEDGEMENTS

I would like to express profound gratitude and appreciation to my advisor, Assistant Professor Pithi Chanvorachote, Ph.D. for his invaluable support, encouragement, supervision, useful suggestions throughout this research work, preparing and presentation of this thesis.

I would like to express appreciation to my co-advisor, Associate Professor Pol. Lt. Col. Somsong Lawanprasert, Ph.D. for her valuable advice, guidance and comments for the experimental work and preparing the thesis.

I would like to thank Phisit Khemawoot, Ph.D. for supplying triclosan. I am also highly thankful to Assistant Professor Rataya Luechapudiporn, Ph.D., Assistant Professor Mali Wirotesangthong, Ph.D., Weerapong Prasongchean, Ph.D. and Hasseri Halim, Ph.D. for their valuable comments and suggestions.

I am also thankful to all staff members of the Department of Pharmacology and Physiology and Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University for the laboratory facilities and their support throughout this research work.

I am as ever, especially indebted to my parents, Mr. Thanet and Mrs. Unchalee Winitthana for their love and support throughout my life. I also wish to thank all professors of Chulalongkorn Dormitory for their kindness and support while I studied. Moreover, my sincere thanks go to my friends who shared their love and experiences with me.

Finally, I would like to thank The 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) for support budget of this thesis and Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty King Bhumibol Adulyadej (Chulalongkorn University) for the financial support.

CONTENTS

	Page
THAI ABSTRACT	iv
NGLISH ABSTRACT	V
ACKNOWLEDGEMENTS	vi
CONTENTS	vii
IST OF TABLES	ix
IST OF FIGURES	xi
IST OF ABBREVIATIONS	×iii
CHAPTER I INTRODUCTION	1
CHAPTER II LITERATURE REVIEWS	4
Cancer	4
Lung cancer	4
Cancer metastasis	6
Cell migration and invasion	8
The role of migratory-related proteins	11
Focal adhesion kinase (FAK)	13
ATP dependent tyrosine kinase (Akt)	15
Rho-family GTPases	17
Anoikis	19
Anoikis resistance	23
The mechanism of anoikis resistance	24
Multicellular aggregation by E-cadherin	24
E-cadherin	24
Multicellular aggregation mediated by E-cadherin and anoikis	
Epithelial-to-mesenchymal transition (EMT)	
N-cadherin	
Vimentin	32



Page

	The inducing signals of EMT	35		
	EMT and anoikis resistance	35		
	EMT and tumorigenicity of cells	36		
	EMT and cell migration	37		
Circulating tumor cells (CTCs)				
Triclosan (TCS)				
CHAPTER III MATERIALS AND METHODS				
	CHAPTER IV RESULTS	66		
	CHAPTER V DISCUSSION AND CONCLUSION	87		
	REFERENCES	94		
	APPENDIX	.104		



Page

Table 1 The reported concentrations of TCS that relevant to concentrations found in
animals, human and environment42
Table 2 The percentage of H460 cell viability determined by MTT assay after
treatment with various concentrations of TCS (0-10 μ M) for 24 h105
Table 3 The percentage of apoptotic cells determined by Hoechst33342/PI staining
assay after treatment with various concentrations of TCS (0-10 μ M) for 24 h
106
Table 4 The percentage of H460 cell viability determined by MTT assay after
treatment with various non-concentrations of TCS (0-7.5 μ M) for 0, 3, 6, 9,
12 or 24 h in detached condition107
Table 5 The percentage of AR cell viability determined by PrestoBlue assay after
treatment with various concentrations of TCS (0-7.5 μ M) for 12, 24 and 48 h
108
Table 6 The percentage of aggregate size of AR cells determined by image analyzer after
treatment with various concentrations of TCS (0-7.5 µM) for 24 h in detached
condition109
Table 7 The percentage of aggregate number of AR cells determined by image
analyzer after treatment with various concentrations of TCS (0-7.5 μ M) for
24 h in detached condition110
Table 8 The relative protein of N-cadherin determined by western blot analysis after AR
cells were treated with TCS (0-7.5 μ M) for 24 h in detached condition111
Table 9 The relative protein of E-cadherin determined by western blot analysis after AR
cells were treated with TCS (0-7.5 μ M) for 24 h in detached condition112
Table 10 The relative protein of vimentin determined by western blot analysis after
AR cells were treated with TCS (0-7.5 μ M) for 24 h in detached condition
113
Table 11 The relative protein of slug determined by western blot analysis after AR cells
were treated with TCS (0-7.5 µM) for 24 h in detached condition114

Page
Table 12 The relative protein of snail determined by western blot analysis after AR cells
were treated with TCS (0-7.5 μ M) for 24 h in detached condition
Table 13 The percentage of colony number of AR cells determined by image
analyzer after treatment with various concentrations of TCS (0-7.5 μ M) for
10 days in colony formation assay116
Table 14 The percentage of colony size of AR cells determined by image analyzer
after treatment with various concentrations of TCS (0-7.5 μ M) for 10 days
in colony formation assay117
Table 15 Relative cell migration of AR cells determined by transwell migration assay
after cells were pretreated with non-toxic concentrations of TCS (0-7.5 μ M)
for 24 h in detached condition and then subjected to transwell assay for
24 h118
Table 16 Relative cell invasion of AR cells determined by transwell invasion assay
after cells were pretreated with non-toxic concentrations of TCS (0-7.5 μ M)
for 24 h in detached condition and then subjected to transwell assay for
24 h119
Table 17 The relative protein of pFAK/FAK determined by western blot analysis after AR
cells were pretreated with TCS (0-7.5 μ M) for 24 h in detached condition and
then attached on conventional culture dishes for 4 h120
Table 18 The relative protein of pAkt/Akt determined by western blot analysis after AR
cells were pretreated with TCS (0-7.5 μ M) for 24 h in detached condition and
then attached on conventional culture dishes for 4 h121
Table 19 The relative protein of Rac1-GTP determined by western blot analysis after AR
cells were pretreated with TCS (0-7.5 μ M) for 24 h in detached condition and
then attached on conventional culture dishes for 4 h122
Table 20 The relative protein of RhoA-GTP determined by western blot analysis after AR
cells were pretreated with TCS (0-7.5 μ M) for 24 h in detached condition and
then attached on conventional culture dishes for 4 h

LIST OF FIGURES

	Page
Figure 1 The main steps of metastatic cascade	7
Figure 2 Mechanisms of cancer cell motility	10
Figure 3 Steps in cell movement	11
Figure 4 Focal adhesion kinase and signaling pathway in cell migration	13
Figure 5 Focal adhesion kinase, phosphorylation sites and downstream signaling	
events	14
Figure 6 Phosphoinositide 3 kinase (PI3K)/Akt signaling pathway	16
Figure 7 The Rho GTPase cycle	18
Figure 8 The functions of Rho GTPases in a migrating cell	19
Figure 9 Survival signaling pathways	20
Figure 10 Anoikis signaling pathways	22
Figure 11 Anoikis resistance and cancer metastasis	23
Figure 12 Cadherin domain structure	25
Figure 13 E-cadherin promotes anoikis resistance, cell proliferation and cell migra	ation
by mediate cell-cell aggregation of tumor cells	.26
Figure 14 Type III of EMT	.29
Figure 15 EMT process and EMT-related proteins.	.29
Figure 16 The role of N-cadherin in EMT process	.31
Figure 17 Vimentin's role in cancer	.33
Figure 18 The role of CTCs in metastatic cascade	.39
Figure 19 The chemical structure of TCS	40
Figure 20 The metabolic pathways of TCS in human	.41
Figure 21 Apoptotic cells and necrotic cells in Hoechst33342 and PI co-staining	.48
Figure 22 The principle of PrestoBlue assay	.50
Figure 23 Colony formation assay	.52
Figure 24 The characterization of filopodia by phalloidin-rhodamine staining assay	.53
Figure 25 Boyden chamber assay (Transwell migration assay)	.54
Figure 26 Boyden chamber assay (Transwell invasion assay)	.55
Figure 27 Conceptual Framework	.58



				Page
Figure :	Experimenta	l designs		60
Figure :	The cytotoxic	effect of triclosan (TC	S) on H460 cells	66
Figure :	Mode of cell	death induced by tri	closan (TCS)	68
Figure :	The effect of	f triclosan (TCS) on H	160 cells anoikis	69
Figure :	Multicellular	aggregation of anoiki	s resistant cells (AR cell	s)69
Figure :	The effect of	triclosan (TCS) on an	oikis resistant cell (AR ce	ell) viability in
	detached co	ondition		70
Figure :			ell-cell interaction of an	
Figure :	Aggregate siz	e and aggregate num	ber of anoikis resistant	cells (AR cells)
	after treatm	ent with triclosan (TC	S) at 0-7.5 µM for 24 h	in detached
	condition			72
Figure :	Effect of tricl	osan (TCS) on E-cadh	erin and EMT markers	73
Figure :	The immuno	blot signals of EMT-re	elated proteins	75
Figure :	Effect of TCS	-mediated EMT on tu	ımorigenic ability of and	oikis resistant cells
	(AR cells)			77
Figure :	Colony num	ber and colony size in	n response to triclosan	(TCS) of anoikis
	resistant cel	ls (AR cells)		78
Figure	Effects of TC	S-mediated EMT on o	cell polarity and filopoc	lia formation of
	anoikis resis	tant cells (AR cells)		80
Figure	Effects of TC	S-mediated EMT on r	nigratory ability of anoil	kis resistant cells
	(AR cells)			81
Figure	Effects of TC	S-mediated EMT on i	nvasive ability of anoiki	s resistant cells (AR
	cells)			82
Figure	Effect of TCS	-mediated EMT on m	nigratory-related protein	s84
Figure	The immuno	blot signals of migrat	ory-related proteins	86
Figure	The conclud	e effects of triclosan	(TCS) to induce EMT pr	ocess in circulating
	tumor cells	(CTCs)		93

% = percentage

°C = degree Celsius

μg = microgram (s)

μl = microliter (s)

 μM = micromolar

Akt = adenosine triphosphate dependent tyrosine kinase

ANOVA = analysis of variance

APAF = apoptosis protease activating factor

AR = androgen receptor

AR cells = anoikis resistant cells

ATP = adenosine triphosphate

Bak = Bcl-2 homologous antagonist killer

Bax = Bcl-2-associated X protein

Bcl-2 = B-cell lymphoma 2

Bcl-XL = B-cell lymphoma-extra large

bHLH = basic helix-loop-helix

Bid = BH3 interacting-domain death agonist

Bim = Bcl-2-like protein 11

BRCA2 = breast cancer 2

BSA = bovine serum albumin

 Ca^{2+} = calcium ion

Cdc42 = cell division cycle 42

 CO_2 = carbon dioxide

CTCs = circulating tumor cells

CR = cytokine receptor

DFF40 = DNA fragmentation factor 40 kDa

DISC = death-inducing signaling complex

DMSO = dimethyl sulfoxide

DNA = deoxyribonucleic acid

DNMT = DNA methyltransferases



EC = extracellular cadherin domain

ECM = extracellular matrix

EDTA = ethylenediaminetetraacetic acid

EGF = epidermal growth factor

EGFR = epidermal growth factor receptor

EMT = epithelial-to-mesenchymal transition

EPA = The US Environmental Protection Agency

ER = estrogen receptors

ERB4 = receptor tyrosine-protein kinase erbB-4

ERK = extracellular-signal-regulated kinase

et al. = et alibi, and other

FADD = Fas-associated death domain protein

FAK = focal adhesion kinase

FasL = Fas Ligand

FBS = fetal bovine serum

FDA = The US Food and Drug Administration

FGF = fibroblast growth factor

g = gram

GAPs = GTPase activating proteins

GDIs = quanine nucleotide dissociation inhibitors

GDM = global DNA methylation

GDP = guanosine diphosphate

GEFs = guanine nucleotide exchange factors

GF = growth factor

GFR = growth factor receptor

GFRKs = growth factor receptor kinases

GPCR = G-protein-coupled receptor

GTP = guanosine triphosphate

h = hour, hours $H^{\dagger} = hydrogen ion$

HRP = horseradish peroxidase



IgG = immunoglobulin G
IU = international unit

kDa = kilo dalton

MAPK = mitogen-activated protein kinase

MET = mesenchymal-epithelial transition

MDB = methylated DNA-binding domain

min = minute (s)

mg = milligram (s)

ml = milliliter

mM = millimolar

MMPs = matrix metalloproteinases

mTOR = mammalian target of rapamycin

mTORC1 = mammalian target of rapamycin complex 1 mTORC2 = mammalian target of rapamycin complex 2

MTT = 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

Na⁺ = sodium ion

NaCl = sodium chloride nm = nanometer (s)

NSCLC = non-small cell lung cancer

OD = optical density

OMM = outer mitochondrial membrane

p53 = cellular tumor antigen p53 PBS = phosphate-buffered saline

pAkt = phosphorylated adenosine triphosphate dependent tyrosine

kinase

pFAK = phosphorylated focal adhesion kinase PDK1 = phosphoinositide-dependent kinase-1

PI = propidium iodide

PI3K = phosphatidylinositol-3 kinase

PIP2 = polyhydroxyl- phosphatidylinositol (4,5)-bisphosphate

PIP3 = phosphatidylinositol (3,4,5)-trisphosphate

PKB = protein kinase B

PPAR α = peroxisome proliferator-activated receptor alpha

pro-MMPs = pro-matrix metalloproteinases

PUMA = p53 upregulated modulator of apoptosis

Rac1 = Ras-related C3 botulinum toxin substrate 1

RhoA = Ras homolog gene family, member A

Ras = rat sarcoma

RPMI = Roswell Park memorial institute's medium

SCLC = small cell lung cancer
SDS = sodium dodecyl sulfate

SE = standard error

Ser = serine

SF/HGF = scatter factor/hepatocyte growth factor

Src = sarcoma

T3 = triiodothyronine

T4 = thyroxine

t-Bid = truncated form of Bid

TBST = Tris-buffered saline, 0.1% Tween 20

TCS = 2,4,4'-trichloro-2'-hydroxydiphenyl ether

 $TGF-\beta$ = transforming growth factor beta

Tyr = tyrosine

ZEB = zinc finger E-box-binding homeobox

ZO = zonula occludens

